Life Sciences Tools & Diagnostics Industry Update Q3 2024
Read more about M&A activity and trends in this sector
Public Markets Update
The YTD-24 performance of the life sciences tools and diagnostics (LSTDX) large-cap group of stocks has been in line with the S&P 500 Healthcare Index (up 11.0% versus 11.5%). However, compared with the broader S&P 500 Index, the large-cap LSTDX group of stocks is substantially underperforming (up 11.0% versus 21.5%).
The LSTDX mid and small/emerging-cap stock groups, however, have not fared as well as their large cap LSTDX brethren as these groups are down 14.3% and 16.5%, respectively, on a YTD-24 basis.
The good news is that inflation figures are once again trending towards the Fed’s target range and, on a near term basis, the September interest rate cut should provide support for continued performance of the stock market as well as M&A activity. Additionally, biotech financing activity in the public markets, especially with respect to IPOs, has shown significant year-over-year improvement. This uptick in biotech-related public market financings provides support for a significant segment of the LSTDX customer base. Finally, the vast majority of LSTDX businesses have substantially normalized after the C-19 pandemic, which should facilitate more productive conversations between buyers and sellers.
Download the document
Q3 2024 Life Sciences Tools & Diagnostics Newsletter
Download PDFExplore more
Industry
Healthcare
KPMG Corporate Finance LLC’s investment bankers have extensive Healthcare transaction and industry experience, which enables them to understand the industry-specific issues and challenges facing our clients.
Meet our team
In today’s market, you need an advisor with objective insight at every step of the transaction process. We work with you throughout the full deal cycle to create value and successfully execute your deal strategy.
